Bluejay Diagnostics Files 8-K with Press Release
Ticker: BJDX · Form: 8-K · Filed: 2026-04-07T09:09:05-04:00
Sentiment: neutral
Topics: 8-K, press-release, filing
Related Tickers: BJDX
TL;DR
Bluejay Diagnostics dropped an 8-K, likely with news, check the press release.
AI Summary
Bluejay Diagnostics, Inc. filed an 8-K on April 7, 2026, to report a press release dated the same day. The filing includes financial statements and exhibits, but no specific financial figures or operational updates were detailed in the provided text.
Why It Matters
This 8-K filing indicates a public disclosure from Bluejay Diagnostics, Inc., which could contain important updates for investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for a press release and does not contain information indicating immediate financial distress or significant operational changes.
Key Players & Entities
- Bluejay Diagnostics, Inc. (company) — Filer of the 8-K
- 0001704287 (company) — CIK number for Bluejay Diagnostics, Inc.
- April 7, 2026 (date) — Filing date and date of press release
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report a press release dated April 7, 2026, and to include financial statements and exhibits.
What specific financial information is disclosed in the filing?
The provided text does not detail specific financial figures or operational updates; it only lists 'Financial Statements and Exhibits' as part of the filing.
What is the filing date of this 8-K?
The filing date of this 8-K is April 7, 2026.
What is the CIK number for Bluejay Diagnostics, Inc.?
The CIK number for Bluejay Diagnostics, Inc. is 0001704287.
What type of business does Bluejay Diagnostics, Inc. operate in?
Bluejay Diagnostics, Inc. operates in the 'Surgical & Medical Instruments & Apparatus' industry, with a SIC code of 3841.
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2026-04-07 09:09:05
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share BJDX The Nasdaq Stock Mar
Filing Documents
- ea0285343-8k_bluejay.htm (8-K) — 25KB
- ea028534301ex99-1.htm (EX-99.1) — 12KB
- ea028534301_img1.jpg (GRAPHIC) — 5KB
- ea028534301_ex99-1img1.jpg (GRAPHIC) — 2KB
- 0001213900-26-040728.txt ( ) — 220KB
- bjdx-20260407.xsd (EX-101.SCH) — 3KB
- bjdx-20260407_lab.xml (EX-101.LAB) — 33KB
- bjdx-20260407_pre.xml (EX-101.PRE) — 22KB
- ea0285343-8k_bluejay_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 7, 2026, Bluejay Diagnostics, Inc. (the "Company") issued a press release providing an update regarding the status of patient enrollment in its ongoing SYMON-II clinical trial. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be "filed" for the purpose of the Securities Exchange Act of 1934, as amended ("Exchange Act"), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.
01
Item 9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated April 7, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Bluejay Diagnostics, Inc. By: /s/ Neil Dey Neil Dey President and Chief Executive Officer Date: April 7, 2026 2